Skip to content
10-Q

Quarterly Report

Yew Bio-Pharm Group, Inc.

0001493152-21-011687

← back to feed
Filed
May 17, 2021 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2021 · May 14, 2021 51.7M sh
Shares Diluted Q1 2021 · Mar 31, 2021 51.7M sh
Shares Diluted Q1 2021 · Mar 31, 2020 51.7M sh
Capex Q1 2021 · Mar 31, 2021 $24.88K
Capex Q1 2021 · Mar 31, 2020 $644
Operating Cash Flow Q1 2021 · Mar 31, 2021 −$776.33K
Operating Cash Flow restated Q1 2021 · Mar 31, 2020 $1.42M
Short Term Debt Q1 2021 · Mar 31, 2021 $9.16M
Short Term Debt Q1 2021 · Dec 31, 2020 $8.98M
Cash And Equivalents Q1 2021 · Mar 31, 2021 $127.33K
Cash And Equivalents Q1 2021 · Dec 31, 2020 $563.79K
Stockholders Equity Q1 2021 · Mar 31, 2021 $48.14M
Stockholders Equity Q1 2021 · Dec 31, 2020 $45.48M
Stockholders Equity Q1 2021 · Mar 31, 2020 $40.73M
Stockholders Equity Q1 2021 · Dec 31, 2019 $41.39M
Current Liabilities Q1 2021 · Mar 31, 2021 $12.34M
Current Liabilities Q1 2021 · Dec 31, 2020 $10.53M
Total Liabilities Q1 2021 · Mar 31, 2021 $13.79M
Total Liabilities Q1 2021 · Dec 31, 2020 $12.96M
Current Assets Q1 2021 · Mar 31, 2021 $15.76M
Current Assets Q1 2021 · Dec 31, 2020 $9.99M
Total Assets Q1 2021 · Mar 31, 2021 $61.93M
Total Assets Q1 2021 · Dec 31, 2020 $58.45M
Eps Diluted Q1 2021 · Mar 31, 2021 $0.06
Eps Diluted Q1 2021 · Mar 31, 2020 $0.00
Eps Basic Q1 2021 · Mar 31, 2021 $0.06
Eps Basic Q1 2021 · Mar 31, 2020 $0.00
Sga Expense Q1 2021 · Mar 31, 2021 $273.77K
Sga Expense Q1 2021 · Mar 31, 2020 $281.53K
Net Income Q1 2021 · Mar 31, 2021 $2.92M
Net Income Q1 2021 · Mar 31, 2020 $151.41K
Operating Income Q1 2021 · Mar 31, 2021 $2.97M
Operating Income Q1 2021 · Mar 31, 2020 $157.39K
Gross Profit Q1 2021 · Mar 31, 2021 $956.97K
Gross Profit Q1 2021 · Mar 31, 2020 $442.26K
Cost Of Revenue Q1 2021 · Mar 31, 2021 $7.78M
Cost Of Revenue Q1 2021 · Mar 31, 2020 $1.59M
Revenue Q1 2021 · Mar 31, 2021 $8.74M
Revenue Q1 2021 · Mar 31, 2020 $2.03M